In addition, the MGMT promoter methylation status is important in determining TMZ sensitivity in GBM; thus, the possible correlations between CS‐6 treatment and MGMT methylation status, as well as the effect of ATP1A3 on CS‐6‐induced changes in MGMT methylation status, were explored (Figure S1). Here, MGMT is linked to glioblastoma.